ScarPro SA
30.4 FTEScarPro reported total assets of €6.98m at the end of the 2025 financial year (annual accounts filed with the NBB on 19 Oct 2026), with 30.4 full-time equivalents.
The score of ScarPro shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +26 % Total assets +36 % Headcount (avg FTE) +92 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
ScarPro's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 19 Oct 2026
- Year ended 31 Dec 2024filed on 13 Oct 2025
- Year ended 31 Dec 2023filed on 21 Nov 2024
- Year ended 31 Dec 2022filed on 23 Aug 2023
- Year ended 31 Dec 2021filed on 25 Aug 2022
ScarPro's financial analysis
- Solvency25.1%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of ScarPro
ScarPro's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0451.049.505
- VAT number
- BE0451049505
- Peppol
- Registered · 0208:0451049505 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 30 Sep 1993
- Registered office
- 9880 Aalter
- Size
- Small · 30.4 FTE
- Latest accounts
- 2025 · filed on 19 Oct 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
ScarPro (SA) has been based in Aalter since 1993, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of €3.11m and equity of €1.75m; its revenue is not published. With 30.4 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 25.1%, below the median of its sector (46.0%).
Companies similar to ScarPro
Companies in the same business, of comparable size and area, outside its group.
- Servicov Wholesale of pharmaceutical and medical goods Ghent · balance sheet €3.54m
- Celyntra Therapeutics Wholesale of pharmaceutical and medical goods Mont-Saint-Guibert · balance sheet €8.20m
- Etablissements Henri Nootens Wholesale of pharmaceutical and medical goods Schaerbeek · balance sheet €5.13m
- Dubavo Wholesale of pharmaceutical and medical goods Lo-Reninge · balance sheet €3.97m
- P&R Bidco Wholesale of pharmaceutical and medical goods Diepenbeek · balance sheet €12.7m
- LPG Benelux Wholesale of pharmaceutical and medical goods Drogenbos · balance sheet €3.55m
- Euromedix Point OF Care Wholesale of pharmaceutical and medical goods Leuven · balance sheet €3.24m
- GHX Europe Wholesale of pharmaceutical and medical goods Brussels · balance sheet €2.81m
Frequently asked questions about ScarPro
What is the revenue of ScarPro?
ScarPro files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of ScarPro?
In Belgium, the VAT number is the company number prefixed with BE: BE0451049505 for ScarPro, if the company is VAT-registered. Its company number (CBE) is 0451.049.505.
Where is the registered office of ScarPro?
According to the CBE register, the registered office of ScarPro is in 9880 Aalter.
What is the equity of ScarPro?
At the close of the 2025 financial year, the equity of ScarPro amounts to 1,751,156 €, a solvency of 25.1% of total assets.
How many people work at ScarPro?
30.4 full-time equivalents on average according to the 2025 social balance sheet.
Who manages ScarPro?
The register lists 2 active mandates at ScarPro. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of ScarPro
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →